Transforming Lives

Through a new class of safe, durable cancer treatments.

In The News

    • APR 05 2018

    Musella Foundation About ONC201 Clinical Trials in Pediatric and Adult Patients with H3 K27M Glioma

    Brain Tumor News Blast Issue 5,656 (Wednesday, April 4, 2018): ONC201 is an experimental, orally bioavailable, first-in-class small molecule with demonstrated antitumor activity in preclinical models of difficult-to-treat solid and liquid tumors without imparting significant toxicity. It is currently investigated for its safety and efficacy in the following clinical trials: 1) ONC-201 for Recurrent Glioblastomas

    • MAR 29 2018

    OncologyTube: Dr. Chi talks about his ONC201 trial in H3 K27M-mutant gliomas

    In the videos below, Dr. Andrew Chi talks about ONC201 and his Phase II – Adults with Recurrent H3 K27M High-grade Glioma (NCT03295396) at NYU Langone. H3 K27M-mutant gliomas are known to overexpress DRD2, the target that ONC201 utilizes to drive its anti-cancer effects. Andrew S. Chi, MD PhD, Chief of Neuro-Oncology and the Codirector of